This article is behind a pay wall...I just copied
Post# of 36568
(Total Views: 459)
Posted On: 09/28/2020 11:04:50 PM
This article is behind a pay wall...I just copied and pasted relevant section.
Thanks!
https://www.bizjournals.com/southflorida/news...-2020.html
The Big Number
$33 million
Amount that Miramar-based Generex Biotechnology Corp. aims to raise on the Nasdaq in a Series A preferred stock offering. The funding would provide it with working capital and “other general corporate purposes,” including paying dividends on the public stock offering and share repurchases, according to a U.S. Securities and Exchange Commission filing.
Currently listed on the Pink Sheets, Generex would offer 1 million shares starting at $33 each if it is approved to be listed on the Nasdaq under the symbol “GNBTP.”
Generex is banking on its majority-owned subsidiary’s vaccine platform to develop and widely distribute a vaccine for the coronavirus.
The company owns NuGenerex Immune-Oncology. Research on NuGenerex’s Ii-Key peptide vaccine technology showed promising results in SARS and breast cancer patients. The company says the technology can be applied to the coronavirus.
Thanks!
https://www.bizjournals.com/southflorida/news...-2020.html
The Big Number
$33 million
Amount that Miramar-based Generex Biotechnology Corp. aims to raise on the Nasdaq in a Series A preferred stock offering. The funding would provide it with working capital and “other general corporate purposes,” including paying dividends on the public stock offering and share repurchases, according to a U.S. Securities and Exchange Commission filing.
Currently listed on the Pink Sheets, Generex would offer 1 million shares starting at $33 each if it is approved to be listed on the Nasdaq under the symbol “GNBTP.”
Generex is banking on its majority-owned subsidiary’s vaccine platform to develop and widely distribute a vaccine for the coronavirus.
The company owns NuGenerex Immune-Oncology. Research on NuGenerex’s Ii-Key peptide vaccine technology showed promising results in SARS and breast cancer patients. The company says the technology can be applied to the coronavirus.
(2)
(0)